Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Short term Debt (2021 - 2025)

Historic Short term Debt for Verrica Pharmaceuticals (VRCA) over the last 4 years, with Q3 2025 value amounting to $12.5 million.

  • Verrica Pharmaceuticals' Short term Debt changed N/A to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year change of. This contributed to the annual value of $12.9 million for FY2024, which is N/A changed from last year.
  • Per Verrica Pharmaceuticals' latest filing, its Short term Debt stood at $12.5 million for Q3 2025.
  • In the past 5 years, Verrica Pharmaceuticals' Short term Debt registered a high of $42.3 million during Q2 2022, and its lowest value of $12.5 million during Q3 2025.
  • Moreover, its 4-year median value for Short term Debt was $40.8 million (2021), whereas its average is $30.0 million.
  • Data for Verrica Pharmaceuticals' Short term Debt shows a peak YoY increase of 327.03% (in 2022) and a maximum YoY decrease of 314.11% (in 2022) over the last 5 years.
  • Quarter analysis of 4 years shows Verrica Pharmaceuticals' Short term Debt stood at $41.7 million in 2021, then rose by 1.44% to $42.3 million in 2022, then tumbled by 69.41% to $12.9 million in 2024, then fell by 3.71% to $12.5 million in 2025.
  • Its Short term Debt was $12.5 million in Q3 2025, compared to $12.7 million in Q2 2025 and $12.8 million in Q1 2025.